Novartis Slashes 114 More Jobs at New Jersey HQ

Key Takeaways

• Novartis cuts 114 jobs at East Hanover HQ, US headcount down 12%
• Company expands US manufacturing workforce 25% to 1,479 employees
• Facing patent cliff, Entresto generic approved, revenue pressure expected 2025‑26
• Novartis invests $23 billion in San Diego R&D hub to boost US footprint
• Recent cuts include 58 medical affairs staff and 427 cardiovascular roles

Pulse Analysis

Novartis’ latest layoff round reflects a broader industry trend where large pharmaceutical firms trim headcount to offset revenue erosion from patent expirations. After spinning off Sandoz, the Swiss giant’s U.S. employee base shrank by nearly 12% year‑over‑year, and the 114‑person cut at its New Jersey headquarters brings the total reductions to several hundred across multiple units. By streamlining commercial and administrative functions, Novartis hopes to preserve operating margins while reallocating resources toward higher‑margin, innovative therapies that will drive growth beyond the 2025‑26 patent cliff.

The timing of the cuts coincides with a significant legal setback: a U.S. court allowed a generic version of Entresto, Novartis’ flagship heart‑failure drug, to enter the market ahead of its 2026 patent expiry. The loss of exclusivity on Entresto, along with upcoming generic competition for Xolair, Promacta and Tasigna, threatens to compress revenue streams. In response, Novartis is doubling down on its pipeline of protected assets such as Cosentyx, Kisqali, Scemblix, Pluvicto and Leqvio, which are secured well into the 2030s and are expected to offset the short‑term profit pressure.

At the same time, Novartis is expanding its U.S. manufacturing and research footprint, highlighted by a $23 billion biomedical research hub in San Diego. This investment not only creates a more resilient supply chain amid geopolitical tariff concerns but also positions the company to accelerate rare‑disease and oncology launches, including BTK inhibitor Rhapsido and kidney‑disease therapies Vanrafia and Fabhalta. By pairing cost reductions with strategic capital deployment, Novartis aims to maintain its competitive edge in a market where efficiency and innovation are increasingly intertwined.